Results 211 to 220 of about 49,811 (292)

Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5‐Year Korean Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5751-5760, July 2026.
ABSTRACT Aims Cardiovascular diseases (CVD) are the leading cause of death worldwide, with excess visceral adipose tissue (VAT) being identified as an independent indicator of poor cardiovascular outcomes. We examined the association between three indices of VAT, namely, metabolic score for visceral fat (METS‐VF), visceral adiposity index (VAI), and ...
A‐Ra Cho, Seok‐Jae Heo, Taehwa Han, Yu‐Jin Kwon   +3 more
wiley   +1 more source

Integration of Continuous Glucose Monitoring With HbA_1c to Improve the Detection of Prediabetes in Asian Individuals: Model Development Study. [PDF]

JMIR Diabetes
Lee MH, Jin S, Febriana E, Lim M, Baig S, Ali SH, Ang IYH, Loh TP, Nastar A, Chia KS, Kong AP, Magkos F, Cook AR, Toh SA.   +13 more
europepmc   +1 more source

Effects of Premeal Versus Postmeal Metformin Administration on Postmeal Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Randomized, 8‐Week Crossover Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5779-5786, July 2026.
ABSTRACT Aims To evaluate the effects of premeal versus postmeal metformin administration on postmeal glycemic control in individuals with type 2 diabetes mellitus receiving metformin monotherapy. Methods All participants were randomly assigned to receive immediate‐release metformin either 30–60 min before or immediately after meal for 4 weeks, and ...
Issaree Rattarasarn, Chatvara Areevut, Khaimook Prachakeserane, La‐Or Chailurkit, Chutintorn Sriphrapradang, Chatchalit Rattarasarn   +5 more
wiley   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Association between periodontal status and salivary interleukin-6 levels in normal-weight and obese individuals with and without prediabetes. [PDF]

Sci Rep
Shaheen MY, Basudan AM, Shaheen RS, AlAhmari FM, Alshibani N, Alssum L, Shaheen FAY, Shaath MR, Al-Kattan R.   +8 more
europepmc   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5492-5507, July 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source

Predictive performance of cardiometabolic indices for prediabetes progression to diabetes and reversion to normoglycemia in adults: a cohort study. [PDF]

Front Nutr
Zhu Y, He Y, Fang S, Chen H, Jiang J, Ming Y, Leng S.   +6 more
europepmc   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5463-5475, July 2026.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Designing and implementing a prediabetes screening in community pharmacies and online prevention program: findings from the PREDICT study. [PDF]

BMC Public Health
Alzubaidi H, Samorinha C, Aljobowry R, Namara KM, Krass I, O'Reilly S, Versace VL, Abdelrahim DN, Alzoubi KH.   +8 more
europepmc   +1 more source